J&J Files 8-K/A Amendment with Debt Details

Ticker: JNJ · Form: 8-K/A · Filed: 2025-01-22T00:00:00.000Z

Sentiment: neutral

Topics: debt-filing, amendment, financial-exhibits

Related Tickers: JNJ

TL;DR

J&J dropped an 8-K/A amendment detailing its various notes due between 2028 and 2044.

AI Summary

Johnson & Johnson filed an 8-K/A amendment on January 22, 2025, to report financial statements and exhibits. This filing specifically includes details about various notes due in November 2028, November 2032, 2035, November 2036, and November 2044, with coupon rates ranging from 1.150% to 3.550%.

Why It Matters

This filing provides updated information on Johnson & Johnson's outstanding debt instruments, offering transparency to investors regarding the company's long-term financing structure.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, primarily providing updated financial exhibits and debt instrument details, with no new material events disclosed.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 8-K/A filing by Johnson & Johnson?

The purpose of this 8-K/A filing is to amend a previous report and provide updated financial statements and exhibits.

What specific debt instruments are detailed in this filing?

The filing details notes due in November 2028, November 2032, 2035, November 2036, and November 2044.

What is the earliest maturity date for the notes mentioned in the filing?

The earliest maturity date for the notes mentioned is November 2028.

What is the highest interest rate mentioned for the debt instruments?

The highest interest rate mentioned is 3.550% for notes due November 2044.

When was this 8-K/A filing submitted to the SEC?

This 8-K/A filing was submitted to the SEC on January 22, 2025.

From the Filing

0000200406-25-000007.txt : 20250122 0000200406-25-000007.hdr.sgml : 20250122 20250122165507 ACCESSION NUMBER: 0000200406-25-000007 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250122 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250122 DATE AS OF CHANGE: 20250122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 25546539 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K/A 1 jnj-20250122.htm 8-K/A jnj-20250122 0000200406 false 0000200406 2025-01-22 2025-01-22 0000200406 us-gaap:CommonStockMember 2025-01-22 2025-01-22 0000200406 jnj:A1.150NotesDueNovember2028Member 2025-01-22 2025-01-22 0000200406 jnj:A3.20NotesDueNovember2032Member 2025-01-22 2025-01-22 0000200406 jnj:A1.650NotesDue2035Member 2025-01-22 2025-01-22 0000200406 jnj:A3.350NotesDueNovember2036Member 2025-01-22 2025-01-22 0000200406 jnj:A3.550NotesDueNovember2044Member 2025-01-22 2025-01-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM  8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  January 22, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 3.20% Notes Due November 2032 JNJ32 New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange 3.350% Notes Due November 2036 JNJ36A New York Stock Exchange 3.550% Notes Due November 2044 JNJ44 New York Stock Exchange EXPLANATORY NOTE This Amendment No. 1 to Form 8-K (“Amendment No. 1”) amends and supplements the Form 8-K filed by Johnson & Johnson on January 22, 2025 solely to align the format of the Reported Sales line for Q4 and Full Year 2024 Sales results

View on Read The Filing